Roles of proteoglycans in reception of the midkine signal

被引:13
作者
Muramatsu, T [1 ]
机构
[1] Nagoya Univ, Sch Med, Dept Biochem, Showa Ku, Nagoya, Aichi 4668550, Japan
关键词
chondroitin sulfate; growth factor; heparan sulfate; midkine; oversulfation;
D O I
10.4052/tigg.13.563
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Midkine (MK) is a heparin-binding growth factor with diverse activities, such as promotion of cell growth, cell survival and cell migration. Pleiotrophin (PTN) / heparin-binding growth-associated molecule (HB-GAM) subsequently identified has sequence similarity to MK, while they are not related to other growth factors. MK promotes growth and the progression of tumor cells and enhances migration of inflammatory cells to participate in neointima formation and renal damages after ischemia. Thus, MK attracts attention as a target molecule to cure diseases. The signaling receptor of MK contains protein tyrosine phosphatase xi (PTPxi), which is a chondroitin sulfate proteoglycan, or syndecans, which are heparan sulfate proteoglycans. MK binds to oversulfated structures in the glycosaminoglycan chains of the proteoglycans, namely chondroitin sulfate E structure and trisulfated structure in heparan sulfate disaccharide units. This binding is necessary for the action of MK. MK is mainly composed of two domains held by disulfide bridges. The more C-terminally located domain has clusters of basic amino acids, which recognize oversulfated region in glycosaminoglycans. The MK receptor also contains a transmembrane glycoprotein, LRP (low density lipoprotein receptor-related protein). The way of interaction of proteoglycans to LRP to transmit the signal to the downstream signaling system, namely P13 kinase to ERK, remains to be clarified.
引用
收藏
页码:563 / 572
页数:10
相关论文
共 64 条
[1]  
Adachi Y, 2000, CANCER RES, V60, P4305
[2]  
Akhter S, 1998, J BIOCHEM-TOKYO, V123, P1127
[3]   Identification of heparin-binding sites in midkine and their role in neurite-promotion [J].
Asai, T ;
Watanabe, K ;
IchiharaTanaka, K ;
Kaneda, N ;
Kojima, S ;
Iguchi, A ;
Inagaki, F ;
Muramatsu, T .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1997, 236 (01) :66-70
[4]  
Choudhuri R, 1997, CANCER RES, V57, P1814
[5]   Reelin is a ligand for lipoprotein receptors [J].
D'Arcangelo, G ;
Homayouni, R ;
Keshvara, L ;
Rice, DS ;
Sheldon, M ;
Curran, T .
NEURON, 1999, 24 (02) :471-479
[6]  
GARVER RI, 1994, CANCER, V74, P1584, DOI 10.1002/1097-0142(19940901)74:5<1584::AID-CNCR2820740514>3.0.CO
[7]  
2-V
[8]   Neointima formation in a restenosis model is suppressed in midkine-deficient mice [J].
Horiba, M ;
Kadomatsu, K ;
Nakamura, E ;
Muramatsu, H ;
Ikematsu, S ;
Sakuma, S ;
Hayashi, K ;
Yuzawa, Y ;
Matsuo, S ;
Kuzuya, M ;
Kaname, T ;
Hirai, M ;
Saito, H ;
Muramatsu, T .
JOURNAL OF CLINICAL INVESTIGATION, 2000, 105 (04) :489-495
[9]   Serum midkine levels are increased in patients with various types of carcinomas [J].
Ikematsu, S ;
Yano, A ;
Aridome, K ;
Kikuchi, M ;
Kumai, H ;
Nagano, H ;
Okamoto, K ;
Oda, M ;
Sakuma, S ;
Aikou, T ;
Muramatsu, H ;
Kadomatsu, K ;
Muramatsu, T .
BRITISH JOURNAL OF CANCER, 2000, 83 (06) :701-706
[10]   Solution structure of midkine, a new heparin-binding growth factor [J].
Iwasaki, W ;
Nagata, K ;
Hatanaka, H ;
Inui, T ;
Kimura, T ;
Muramatsu, T ;
Yoshida, K ;
Tasumi, M ;
Inagaki, F .
EMBO JOURNAL, 1997, 16 (23) :6936-6946